You have 9 free searches left this month | for more free features.

City

Palo Alto (1)

Redwood City (1)

San Antonio (1)

Shanghai (1)

Stanford (1)

Condition

COVID-19 (1)

Chronic Hepatitis B (1)

Chronic Hepatitis C (1)

Healthy (1)

Primary Sclerosing Cholangitis (1)

Respiratory Disease (1)

Overall Status

Completed (1)

Not yet recruiting (1)

Recruiting (1)

Unknown status (1)

Sign in for free

Phase

phase 2 (2)

n/a (1)

phase 1 (1)

Sponsor

Paul Bollyky (2)

MTmedical Institute of Health (1)

Shanghai Zhongshan Hospital (1)

Collaborator

BioMonde Preparations Limited (1)

The University of Texas Health Science Center at San Antonio (1)

Intervention

hymecromone (2)

4-methylumbelliferone (heparvit®) (1)

hymecromone tablets (1)

placebo (1)

Study Documents

Intervention Type

drug (4)

other (1)

Funder Type

Other (4)

Study Type

Interventional (4)

Hymecromone

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Primary Sclerosing Cholangitis Trial in Redwood City, Stanford (Hymecromone)

Not yet recruiting

Primary Sclerosing Cholangitis

Hymecromone

Redwood City, California
+1 more

Nov 1, 2022

COVID-19 Trial in Shanghai (Hymecromone tablets, Placebo)

Recruiting

COVID-19

Hymecromone tablets
Placebo

Shanghai, Shanghai, China

Zhong Shan Hospital affiliated to Fudan University

Jun 7, 2022

Healthy, Respiratory Disease Trial in Palo Alto (hymecromone)

Completed

Healthy
Respiratory Disease

hymecromone

Palo Alto, California

Stanford University

Jun 11, 2021

Chronic Hepatitis C, Chronic Hepatitis B Trial in San Antonio (4-Methylumbelliferone (Heparvit®))

Unknown status

Chronic Hepatitis C
Chronic Hepatitis B

4-Methylumbelliferone (Heparvit®)

San Antonio, Texas

University Health Center Downtown "Brady/Green", 527 North Leona

Sep 7, 2006